[go: up one dir, main page]

WO2007075672A3 - Marqueurs pour le pronostic du cancer - Google Patents

Marqueurs pour le pronostic du cancer Download PDF

Info

Publication number
WO2007075672A3
WO2007075672A3 PCT/US2006/048411 US2006048411W WO2007075672A3 WO 2007075672 A3 WO2007075672 A3 WO 2007075672A3 US 2006048411 W US2006048411 W US 2006048411W WO 2007075672 A3 WO2007075672 A3 WO 2007075672A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer markers
prognostic cancer
prognostic
cancer
prognosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/048411
Other languages
English (en)
Other versions
WO2007075672A2 (fr
Inventor
U Margaretha Wallon
George C Prendergast
Karen A Knudsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lankenau Institute for Medical Research
Original Assignee
Lankenau Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lankenau Institute for Medical Research filed Critical Lankenau Institute for Medical Research
Publication of WO2007075672A2 publication Critical patent/WO2007075672A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007075672A3 publication Critical patent/WO2007075672A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés, des kits et des compositions permettant de diagnostiquer, d'évaluer le pronostic ou de surveiller la progression d'un cancer chez un sujet, en particulier d'un cancer du sein.
PCT/US2006/048411 2005-12-23 2006-12-20 Marqueurs pour le pronostic du cancer Ceased WO2007075672A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75361905P 2005-12-23 2005-12-23
US60/753,619 2005-12-23

Publications (2)

Publication Number Publication Date
WO2007075672A2 WO2007075672A2 (fr) 2007-07-05
WO2007075672A3 true WO2007075672A3 (fr) 2008-06-26

Family

ID=38218531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048411 Ceased WO2007075672A2 (fr) 2005-12-23 2006-12-20 Marqueurs pour le pronostic du cancer

Country Status (1)

Country Link
WO (1) WO2007075672A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130136689A1 (en) * 2007-06-05 2013-05-30 Christian Rohlff Proteins
US8435749B2 (en) 2008-06-30 2013-05-07 Oncotherapy Science, Inc. Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
KR101621036B1 (ko) * 2011-03-27 2016-05-13 온코스템 다이아그노틱스 (모리셔스) 프라이빗 리미티드 종양 세포를 동정하기 위한 마커, 그의 방법 및 키트
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
CA2967188A1 (fr) 2014-11-14 2016-05-19 Novartis Ag Conjugues anticorps-medicament

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723581A (en) * 1995-05-05 1998-03-03 The Wistar Institute Of Anatomy And Biology Murine and human box-dependent myc-interacting protein (Bin1)
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
WO2002008765A2 (fr) * 2000-07-26 2002-01-31 Stanford University Marqueurs basocellulaires du cancer du sein et leurs utilisations
WO2002097395A2 (fr) * 2001-05-31 2002-12-05 Chiron Corporation Utilisation de p-cadherine comme cible dans la therapie anticancereuse
US20030166021A1 (en) * 1997-06-06 2003-09-04 The Wistar Institute Of Anatomy And Biology Box-dependent Myc-interacting protein (BIN1) compositions and uses therefor
US20040121343A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated Markers for differential diagnosis and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723581A (en) * 1995-05-05 1998-03-03 The Wistar Institute Of Anatomy And Biology Murine and human box-dependent myc-interacting protein (Bin1)
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
US20030166021A1 (en) * 1997-06-06 2003-09-04 The Wistar Institute Of Anatomy And Biology Box-dependent Myc-interacting protein (BIN1) compositions and uses therefor
WO2002008765A2 (fr) * 2000-07-26 2002-01-31 Stanford University Marqueurs basocellulaires du cancer du sein et leurs utilisations
US20030086934A1 (en) * 2000-07-26 2003-05-08 David Botstein Basal cell markers in breast cancer and uses thereof
WO2002097395A2 (fr) * 2001-05-31 2002-12-05 Chiron Corporation Utilisation de p-cadherine comme cible dans la therapie anticancereuse
US20040121343A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated Markers for differential diagnosis and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG M. ET AL.: "Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4", ONCOGENE, vol. 14, 1997, pages 2767 - 2774 *

Also Published As

Publication number Publication date
WO2007075672A2 (fr) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2009037572A3 (fr) Combinaisons de bio-marqueurs du cancer colorectal
WO2008030986A3 (fr) Diagnostic et classification moléculaires de mélanome malin
WO2009036427A3 (fr) Biomarqueurs du cancer de la prostate
WO2007076439A3 (fr) Procede et combinaisons de marqueurs permettant de depister une predisposition au cancer du poumon
EP1922326A4 (fr) Biomarqueurs utiles pour diagnostiquer un cancer de la prostate et procédé d'utilisation de ceux-ci
WO2006089091A3 (fr) Procedes pour la detection de maladie residuelle minimale
WO2008097908A3 (fr) Procédés de diagnostic et de pronostic d'un cancer du poumon
WO2008067065A3 (fr) Procédés, kits et systèmes pour diagnostiquer et pronostiquer le cancer de la prostate en utilisant des biomarqueurs sécrétés
CA2602088C (fr) Marqueurs biologiques du cancer de l'ovaire et du cancer de l'endometre
WO2004060302A3 (fr) Methodes et compositions pour le diagnostic, le pronostic, et le traitement du cancer
IL180997A0 (en) Diagnostic methods and kits utilizing platelet biomarkers for cancer
WO2006113529A3 (fr) Diagnostic d'une sepsie
WO2009115615A3 (fr) Détection et pronostic du cancer du col de l’utérus
WO2008008500A3 (fr) Procédés pronostiques du cancer à partir de la localisation subcellulaire de biomarqueurs
GB0720113D0 (en) Diagnostic, prognostic and predictive testing for cancer
WO2008061104A3 (fr) Méthodes et trousses de détection de marqueurs du cancer de la prostate
WO2004061410A3 (fr) Biomarqueurs seriques du cancer du poumon
WO2007095644A3 (fr) reactifs et procedes pour le pronostic et la stadification pathologique d'un cancer
WO2009055820A3 (fr) Biomarqueurs de protéines salivaires pour le cancer de la bouche de l'homme
WO2013057581A8 (fr) Biomarqueurs composites pour criblage, diagnostic et pronostic non invasifs de cancer colorectal
WO2007120362A3 (fr) Adenovirus adipogenes comme biomarqueur d'une maladie
WO2007064776A3 (fr) Marqueurs du cancer du sein
WO2013028807A3 (fr) Biomarqueurs du carcinome cellulaire rénal et leurs utilisations
WO2007056523A3 (fr) Procedes de diagnostic et de surveillance de la progression d'un cancer
WO2006034032A3 (fr) Marqueurs biologiques destines au cancer du sein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848889

Country of ref document: EP

Kind code of ref document: A2